The Lancet Neurology in conversation with
The Lancet Neurology in conversation with
The Lancet Group
Alexandra Durr on riluzole in patients with spinocerebellar ataxia type 2
7 minutes Posted Feb 22, 2022 at 10:00 am.
0:00
7:55
Download MP3
Show notes

Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.

Read the full article:
Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL)